Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)
Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)
复制标题
DOI：
10.2147/clep.s191914
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Lashkariani, Mariam
中科院分区：
文献类型：
--
作者：
Ludvigsson, Jonas F.;Lashkariani, Mariam
ESSERO研究构成了一种新的方法来检查胃肠道疾病的病因和预后，其中组织病理学起着重要作用。在2015年至2017年期间，联系了瑞典的所有病理科（n=28），并要求获得胃肠道（咽至肛门）、肝脏、胆囊和胰腺的组织病理学记录数据。对于每名个体，当地组织病理学IT人员检索了个人身份证号、组织病理学日期、地形图（活检部位）、形态学（活检外观）和可用的自由文本等数据。总体而言，1965年至2017年间，有210万名独立个体的组织病理学记录数据可用，但数据条目数量为610万，因为许多研究参与者进行了不止一次活检。具有组织病理学数据的指数个体与来自一般人群的多达五个对照相匹配。我们还确定了所有一级亲属（父母、孩子、全兄弟姐妹）以及指标个人的第一任配偶。总研究人群包括1300万人。所有研究参与者的数据都与瑞典国家卫生保健登记册相关联，不仅可以研究胎儿和围产期状况以及未来胃肠道疾病的风险，还可以研究合并症和并发症（包括癌症和死亡）的风险。此外，ESTRO数据库使研究人员和从业人员能够确定目前未在国家登记册中编入索引的诊断和疾病表型（包括疾病前兆）。ESSERO数据库提高了国家卫生登记册中已记录疾病的敏感性和特异性。本文是对ESSERO数据库的概述。
The ESPRESSO study constitutes a novel approach to examine the etiology and prognosis of gastrointestinal disease in which histopathology plays a prominent role. Between 2015 and 2017, all pathology departments (n=28) in Sweden were contacted and asked to procure histopathology record data from the gastrointestinal tract (pharynx to anus), liver, gallbladder, and pancreas. For each individual, local histopathology IT personnel retrieved data on personal identity number, date of histopathology, topography (where the biopsy is taken), morphology (biopsy appearance), and where available free text. In total, between 1965 and 2017, histopathology record data were available in 2.1 million unique individuals, but the number of data entries was 6.1 million because more than one biopsy was performed in many of the study participants. Index individuals with histopathology data were matched with up to five controls from the general population. We also identified all first-degree relatives (parents, children, full siblings), and the index individual's first spouse. The total study population consisted of 13.0 million individuals. Data from all the study participants have been linked to Swedish National Healthcare Registers allowing research not only on such aspects as fetal and perinatal conditions and the risk of future gastrointestinal disease but also on the risk of comorbidity and complications (including cancer and death). Furthermore, the ESPRESSO database allows researchers and practitioners to identify diagnoses and disease phenotypes not currently indexed in national registers (including disease precursors). The ESPRESSO database increases the sensitivity and specificity of already-recorded diseases in the national health registers. This paper is an overview of the ESPRESSO database.